Current antigen targets in clinical trials for CAR-T cell therapy for lung cancer include MUC-1, CEA, HER2, mesothelin, receptor tyrosine kinase-like orphan receptor 1 (ROR1), glypican-3 (GPC3), EGFR, and PD-1 [228]. This evidence concerns the gene GPC3 and lung cancer.